Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study highlights significant psychosocial distress and access barriers faced by South Asian patients, suggesting improved provider education, broader insurance coverage, and enhanced patient assistance programs as necessary steps to achieve equitable healthcare access.